WO2024075131A1 - Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof - Google Patents

Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof Download PDF

Info

Publication number
WO2024075131A1
WO2024075131A1 PCT/IN2022/051056 IN2022051056W WO2024075131A1 WO 2024075131 A1 WO2024075131 A1 WO 2024075131A1 IN 2022051056 W IN2022051056 W IN 2022051056W WO 2024075131 A1 WO2024075131 A1 WO 2024075131A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
acetate
upadacitinib
suitable solvent
Prior art date
Application number
PCT/IN2022/051056
Other languages
French (fr)
Inventor
Srinivasan ABAYEE KALIYAPERUMAL
Ranga Reddy Vangala
Shyam Sundar Reddy TALASANI
Suresh Kumar Krishnammagari
Srinivasachary CHINTALAPATI
Srinivasa Rao CHEEDI
Thirupathi Kotte
Anitha GATTU
Naga Jyothi Movva
Venkateswar Rao CIRUSANAGANDLA
Rushya Rao YAJJUVARAPU
Shankar Reddy BUDIDETI
Pulla Reddy Muddasani
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of WO2024075131A1 publication Critical patent/WO2024075131A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds

Definitions

  • the present invention relates to a Co-crystal of Upadacitinib.
  • the present invention relates to a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ⁇ 0.2° 2 ⁇ and further peaks additional at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ⁇ 0.2° 2 ⁇ ” and process for the preparation thereof.
  • DATA Upadacitinib and Diacetyl-D-tartaric acid
  • PXRD X-ray diffraction pattern
  • Upadacitinib Diacetyl-D-tartaric acid (DATA) BACKGROUND OF THE INVENTION
  • Upadacitinib is the adopted name of drug compound having a chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2- trifluoroethyl)- pyrrolidine-l-carboxamide compound of Formula-Ia and structure as below.
  • Formula-Ia Upadacitinib also known as ABT-494, is potent and selective JAK inhibitor approved for rheumatoid arthritis (RA).
  • Upadacitinib is approximately 74-fold selective for JAK1 over JAK2 in cellular assays dependent on specific, relevant cytokines. Upadacitinib demonstrates efficacy in rat arthritis models.
  • ACR20 American College of Rheumatology 20 percent improvement criteria
  • Patients were randomized to receive immediate-release Upadacitinib at 3, 6, 12, or 18 mg twice daily or matching placebo. The researchers found that significantly more patients receiving Upadacitinib achieved an ACR20 response (53 to 71 percent) versus placebo (34 percent).
  • Upadacitinib may spare JAK2 and JAK3 dependent signaling.
  • US RE47221 discloses a process for the preparation of Upadacitinib of Formula- Ia as illustrated in the Scheme-I below.
  • the compound of Formula-II is deprotected in the presence of trifluoroacetic acid/HCl in 1,4-dioxane solvent to obtain compound of Formula-III, which is further reacted with benzyl-2,5- dioxopyrrolidine-1-yl-carbonate to obtain compound of Formula-IV followed by reaction with HBr/oxalyl chloride in the presence of trimethylsilyldiazomethane to obtain compound of Formula-V.
  • Condensation of compound of Formula-V with compound of Formula-VI in the presence of NaH in DMF to obtain compound of Formula-VII, which further undergoes cyclization in the presence of dithaiophosphetane to obtain compound of Formula-VIII.
  • the described upadacitinib salts include a tartrate hydrate, various hydrochloride solvates designated Form AA, Form BB and Form CC as well as crystalline forms of L-Maleate salt designated Form AAA and Form BBB, respectively.
  • Crystalline Form-C Hemihydrate of Upadacitinib disclosed in US 9951080 is characterized by X-ray diffraction pattern (PXRD) comprising the peaks at 7.7, 7.9, 9.6, 10.3, 13.4, 13.9, 15.1, 15.5, 15.9, 17.0, 17.2, 17.8, 18.1, 18.3, 19.3, 19.7, 20.5, 20.9, 21.7, 21.9, 22.2, 23.5, 24.4, 24.9, 28.2 and 29.5° 2 ⁇ .
  • PXRD X-ray diffraction pattern
  • US ‘ 080 further discloses that the peaks at 7.9, 10.3, 13.4, 15.1, 15.5, 17, 20.9 and 21.7 are major characteristic peaks for Crystalline Form-C Hemihydrate of Upadacitinib.
  • Crystalline Form-D Anhydrous of Upadacitinib disclosed in US 9951080 is characterized by X-ray diffraction pattern (PXRD) comprising the peaks at 4.0, 8.0, 9.7, 14.2, 14.5, 19.0 and 20.3° 2 ⁇ .
  • US ‘080 further discloses that the peaks at 4.0, 9.7, 14.2, 14.5, 19.0 and 20.3° 2 ⁇ . are major characteristic peaks for Crystalline Form-D anhydrous of Upadacitinib.
  • US 20220002306 A1 discloses a Crystalline form CSI of Upadacitinib (acetic acid solvate).
  • US 20210380596 A1 discloses a Crystalline Form-CSII of Upadacitinib (Anhydrate).
  • EP 3891151 A1 discloses a Crystalline Phosphate salt of Upadacitinib.
  • WO 2020115213 A1 discloses acetic acid solvate of Upadacitinib.
  • CN 112110929 A1 discloses Crystalline Forms of CM-I and CM-II of Upadacitinib.
  • CN 112409362 A1 discloses Crystalline Forms of Upadacitinib intermediate.
  • US 20220041611 A1 discloses crystal form-A of the Di-p-toluoyl-L-tartrate of Upadacitinib, oxalate of Upadacitinib and PTSA salt of Upadacitinib.
  • WO 2021/244323 A1 discloses Crystal form CSIV of Upadacitinib (Sebacic acid Co-crystal) and Crystal form CSV of Upadacitinib (Glutaric acid Co-crystal).
  • US 20220204519 A discloses a Crystal form CSVI of Upadacitinib (Succinic acid Co-crystal) and Crystal form CSVII of Upadacitinib (Adipic acid Co-crystal).
  • IN 202041025283 A discloses a crystalline Form-US of Upadacitinib and succinic acid (co-crystal).
  • IN 202041052794 A discloses a Crystalline Form-UF of Upadacitinib and fumaric acid.
  • the above prior art references disclose various polymorphic forms of Upadacitinib free base. None of the prior art discloses co-crystals of Upadacitinib and Diacetyl- D-tartaric acid (DATA).
  • the inventors of the present invention have developed a novel co-crystal of Upadacitinib and Diacetyl-D-tartaric acid which is more stable and suitable for making formulation.
  • the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ⁇ 0.2° 2 ⁇ and further peaks at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ⁇ 0.2° 2 ⁇ ” and process for the preparation thereof.
  • DATA Upadacitinib and Diacetyl-D-tartaric acid
  • PXRD powder X-ray diffraction pattern
  • the present invention further provides Co-crystal of Upadacitinib and Diacetyl-D- tartaric acid (DATA) characterized in that its powder X-ray powder diffraction pattern is basically the same as that of FIG.1.
  • the present invention also provides a process for preparing the compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), Formula-I Diacetyl-D-tartaric acid (DATA) comprising the steps of: a) reacting compound of Formula-Va, Formula-Va with compound of Formula-VI Formula-VI in presence of a base in a suitable solvent to produce compound of Formula- XIII.
  • DPTA (+)-Di-p-toluoyl-D-tartaric Acid
  • CDI Carbonyldiimidazole
  • SCXRD Single Crystal X-ray Diffraction
  • Figure 2 Illustrates the PXRD diagram of compound of Formula-I which is a co- crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA).
  • DATA Upadacitinib and Diacetyl-D-tartaric acid
  • the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1,7.4, 9.7, 10.6, 12.5, 14.3, 15.9, 16.5, 21.3 and 24.8° ⁇ 0.2° 2 ⁇ ” and process for the preparation thereof.
  • PXRD powder X-ray diffraction pattern
  • the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ⁇ 0.2° 2 ⁇ and further the peaks at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ⁇ 0.2° 2 ⁇ ” and process for the preparation thereof.
  • the present invention further provides a Co-crystal of Upadacitinib and Diacetyl- D-tartaric acid characterized in that its X-ray powder diffraction pattern is basically the same as that of FIG.1.
  • the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD), wherein the peak at 7.9 and 10.3 are absent in the PXRD of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid in the present invention.
  • PXRD powder X-ray diffraction pattern
  • the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD), wherein the peak at 4.0 is absent in the PXRD of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid in the present invention.
  • the present invention further provides Co-crystal comprises Upadacitinib and Diacetyl-D-tartaric acid within the same crystalline phase in a molar ratio of 1: 0.5.
  • SCXRD Single Crystal X-ray Diffraction
  • the co-crystal may be present in crystalline form.
  • the present invention also provides a process for preparing the compound of Formula-I of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), comprising the steps of: a) reacting compound of Formula-Va, with compound of Formula-VI in presence of a base in a suitable solvent to produce compound of Formula- XIII. b) cyclizing the compound of Formula-XIII in-situ in presence of Trifluoroacetic anhydride (TFAA) in a suitable solvent to produce compound of Formula-XIV.
  • TFAA Trifluoroacetic anhydride
  • the base used in Step-a) is an organic or inorganic base.
  • the organic base is selected from N,N-diisopropylamine, N,N-diisopropylethylamine triethylamine, N,N- dimethylamine, trimethylamine, pyridine;
  • the inorganic base is selected from sodium hydride, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate, or mixture thereof. preferably sodium hydride.
  • the solvent used in step a) is an organic solvent, for example an aprotic polar solvent comprises N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixture thereof preferably dimethylformamide; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof.
  • an aprotic polar solvent comprises N,N-dimethylformamide, dimethylsulfoxide, aceton
  • the reaction may be performed from -60 ° C to 60 ° C for 30 min to 48 hours and then compound of Formula-XIII can be obtained by a usual procedure.
  • the obtained compound-XIII can be used in the next reaction directly without isolation.
  • the solvent used in step b) is an organic solvent, for example an aprotic polar solvent.
  • Appropriate aprotic polar solvents can comprise N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixtures thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof.
  • step c) can be an inorganic acid comprising HCl, HBr in water or in organic solvents Methanol, Isopropyl alcohol acetic acid preferably HBr in acetic acid.
  • the solvent used in step c) is an organic solvent, for example an aprotic polar solvent comprises N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixture thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, 2-Ethoxyethyl acetate or mixture thereof organic acid comprises Formic acid, Acetic acid Propionic acid or mixture thereof preferably Acetic acid
  • the organic acid used in step c) is selected from tartaric acid, Dibenzoyl-D-tartaric acid, Di-p-toluoyl-D-tartaric acid, Dia
  • the base used in step d) is selected from triethylamine, N,N-diisopropylamine, N,N- diisopropylethylamine, N,N-dimethylamine, trimethylamine, pyridine or mixture thereof.
  • the solvent used in step d) is an organic solvent, for example an aprotic polar solvent comprises dichloromethane, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, or mixture thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert- butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof.
  • an aprotic polar solvent comprises dichloromethane, N,N-dimethylformamide, dimethyl
  • the reaction may be performed from 0 ° C to 60 ° C for 30 min to 48hours and then compound of Formula-XVI can be obtained by a usual procedure.
  • the obtained compound-XVI can be used in the next reaction directly without isolation.
  • the base used in step e) is selected from sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate, or mixture thereof.
  • the suitable solvent used in step e) is selected from tetrahydrofuran, dichloromethane, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, water or mixture thereof preferably tetrahydrofuran;
  • the reaction may be performed from 0 ° C to 60 ° C for 30 min to 48 hours and then compound of Formula-XVII can be obtained by a usual procedure.
  • the suitable solvent used in step f) is an organic solvent, for example an alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ester comprises ethyl acetate, methyl acetate, n-butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof.
  • an alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof
  • ester comprises ethyl acetate, methyl acetate, n-butyl acetate, isopropyl acetate, methoxy
  • the anti-solvent used in step f) is selected from ethyl acetate, methyl acetate, n- butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof.
  • n-butyl acetate Preferably n-butyl acetate.
  • the reaction may be performed from 0 ° C to 60 ° C for 30 min to 48hours and then compound of Formula-I of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA).
  • Advantages of present invention 1.
  • the above reaction scheme is straightforward; minimizes the unit operation, and isolates the intermediate as filterable solid. 2. Controlling of racemization and achieving required chemical and chiral purity. 3.
  • EXAMPLE-1 PREPARATION OF (3R,4S)-3-[2-[[(1,1-DIMETHYLETHOXY) CARBONYL][5-[(4-METHYLPHENYL)SULFONYL]-5H-PYRROLO[2,3-b] PYRA-ZIN-2-YL]AMINO]ACETYL]-4-ETHYL-1-PYRROLIDINE CARBOXYLICACID PHENYL METHYL ESTER OF FORMULA-XIII.
  • the reaction mixture was quenched with a mixture of acetic acid (38.6 g, 1.0 m.eq) and DMF (40 mL) mixture after the reaction was completed by HPLC.
  • the product was extracted with toluene twice (2.5 L, 1.25 L) and the combined organic layers were washed with sodium chloride (1.25 L).
  • the organic layer is concentrated and co-distilled with acetonitrile to get Compound of Formula-XIII as a syrupy mass.
  • the resulted syrupy mass dissolved in acetonitrile (2.5 L) and used for next step.
  • EXAMPLE-2 PREPARATION OF (3S,4R)-3-ETHYL-4-[3-[(4-METHYL PHENYL)SULFONYL]-3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]PYRAZIN-8-YL]-1- PYRROLIDINE CARBOXYLIC ACID PHENYLMETHYL ESTER OF FORMULA-XIV.
  • trifluoroacetic anhydride 270.3 g, 1.28 moles
  • reaction mixture was agitated at 25-30°C for 2 hours, after which the mass was diluted with DM water and washed three times with MTBE (5000 mL). Then the aqueous layer is back- extracted with dichloromethane (2*1250 mL) after pH adjustment by using aqueous ammonia (500 mL) at 0-10°C. The combined organic layers were washed with DM water (1250 mL) and the organic layers were concentrated under reduced pressure.
  • EXAMPLE-04 PREPARATION OF (3S,4R)-3-ETHYL-4-[5-(P-TOLYL SULFONYL)-1,5,7,10-TETRAZATRICYCLO[7.3.0.02,6]DODECA-2(6),3,7,9, 11-PENTAE-N-12-YL]-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1- CARBOXAMIDE OF FORMULA-XVI.
  • EXAMPLE-05 PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a] PYRROLO[2,3-e]PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROMETHYL)- PYRROLIDINE-1-CARBOXAMIDE, SODIUM P-TOLUENESULFONATE OF FORMULA-XVII.
  • EXAMPLE-06 PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2- a]PYRROLO[2,3-e]PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROMETHYL)- PYRROLIDINE-1-CARBOXAMIDE,(+)DIACETYL-D-TARTARICACID (1:0.5) OF FORMULA-I.
  • Compound of Formula-XVII (290g) was added to ethyl acetate (2250 mL) and agitated for 10 minutes before adding DM water (1125 mL) and stirring for another 30 mins.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

5 The present invention relates to a Co-crystal of Upadacitinib. More particularly, the present invention relates to a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 7.4, 9.7, 10.6, 12.5, 14.3, 15.9, 16.6, 21.3 and 24.8° ± 0.2° 2θ" and process for the 10 preparation thereof. (S)(R)Diacetyl-D-tartaric acid (DATA) Formula-I

Description

CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF FIELD OF THE INVENTION The present invention relates to a Co-crystal of Upadacitinib. More particularly, the present invention relates to a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ± 0.2° 2θ and further peaks additional at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ± 0.2° 2θ” and process for the preparation thereof.
Figure imgf000002_0002
Upadacitinib Diacetyl-D-tartaric acid (DATA) BACKGROUND OF THE INVENTION Upadacitinib is the adopted name of drug compound having a chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2- trifluoroethyl)- pyrrolidine-l-carboxamide compound of Formula-Ia and structure as below. Formula-Ia
Figure imgf000002_0001
Upadacitinib, also known as ABT-494, is potent and selective JAK inhibitor approved for rheumatoid arthritis (RA). Upadacitinib is approximately 74-fold selective for JAK1 over JAK2 in cellular assays dependent on specific, relevant cytokines. Upadacitinib demonstrates efficacy in rat arthritis models. Researchers found that the proportion of patients meeting the American College of Rheumatology 20 percent improvement criteria (ACR20) at week 12 was higher with Upadacitinib than placebo (62 to 80 percent versus 46 percent). Patients were randomized to receive immediate-release Upadacitinib at 3, 6, 12, or 18 mg twice daily or matching placebo. The researchers found that significantly more patients receiving Upadacitinib achieved an ACR20 response (53 to 71 percent) versus placebo (34 percent). Preliminary evidence suggests that compared to Tofacitinib, Upadacitinib may spare JAK2 and JAK3 dependent signaling. US RE47221 discloses a process for the preparation of Upadacitinib of Formula- Ia as illustrated in the Scheme-I below. First, the compound of Formula-II is deprotected in the presence of trifluoroacetic acid/HCl in 1,4-dioxane solvent to obtain compound of Formula-III, which is further reacted with benzyl-2,5- dioxopyrrolidine-1-yl-carbonate to obtain compound of Formula-IV followed by reaction with HBr/oxalyl chloride in the presence of trimethylsilyldiazomethane to obtain compound of Formula-V. Condensation of compound of Formula-V with compound of Formula-VI in the presence of NaH in DMF to obtain compound of Formula-VII, which further undergoes cyclization in the presence of dithaiophosphetane to obtain compound of Formula-VIII. Deprotection of compound of Formula-VIII in the presence of HBr to obtain compound of Formula- IX followed by reacting with 2,2,2-trifluoroethanamine in the presence of CDI in DMF to obtain compound of Formula-X. Further, deprotection of compound of Formula-X in the presence of sodium hydroxide followed by resolution using chiral preparative HPLC to obtain Upadacitinib of Formula-(Ia). The synthetic procedure is illustrated in Scheme-I as below: Oxalyl chloride/ THF/ 1,4-Dioxane/ Benzyl 2,5-dioxopyrrolidine- Trimethylsilyl- HCl 1-yl-carbonate diazomethane/HBr Step-I . HCl Step-II Step-III (II) (III) (IV) (V) NaH/DMF Step-IV (VI) HBr Dithaiophosphetane CDI/DMF Step-VI Step-VII Step-V (X) (IX) (VIII) Step-VIII 1. NaOH 2. Chiral preparative HPLC (VII) Upadacitinib of Formula-Ia Scheme-I US9951080 also discloses a process for the preparation of Upadacitinib of Formula- Ia as shown in Scheme II below, by the condensation of compound of Formula-Va with compound of Formula-VIa in the presence of lithium tert butoxide to obtain compound of Formula-VIIa, which undergoes cyclization in the presence of Trifluoroacetic anhydride (TFAA) in pyridine followed by deprotection in the presence of sodium hydroxide to obtain compound of Formula-XI. Further, deprotection of compound of Formula-XI in presence of HCl in EtOH/ EtOAc produces compound of Formula-XII. And, compound of Formula-XII is further reacted with 2,2,2-trifluoroethanamine in the presence of CDI, KOH and Dipotassium phosphate (K2HPO4) to obtain Upadactinib of Formula-Ia. The synthetic procedure is illustrated in Scheme-II as below: LiOtBu 1. TFAA/ Pyridine DMA 2. NaOH Step-I Step-II (VIa) (IV) (Va) (XI) Step-III HCl/ EtOH/ EtOAc (VIIa) .2HCl CDI/ K2HPO4 Step-IV (XII) Upadacitinib (Formula-Ia) Scheme-II US 9951080 discloses various solid-state forms of upadacitinib free base such as Form- A (Isopropyl aetate/ water solvate), Form-B (hydrate), Form-C (Hemihydrate) and Form-D (Anhydrous) and different acid addition salts of upadacitinib were disclosed in US9951080. The described upadacitinib salts include a tartrate hydrate, various hydrochloride solvates designated Form AA, Form BB and Form CC as well as crystalline forms of L-Maleate salt designated Form AAA and Form BBB, respectively. Crystalline Form-C Hemihydrate of Upadacitinib disclosed in US 9951080 is characterized by X-ray diffraction pattern (PXRD) comprising the peaks at 7.7, 7.9, 9.6, 10.3, 13.4, 13.9, 15.1, 15.5, 15.9, 17.0, 17.2, 17.8, 18.1, 18.3, 19.3, 19.7, 20.5, 20.9, 21.7, 21.9, 22.2, 23.5, 24.4, 24.9, 28.2 and 29.5° 2θ. US ‘ 080 further discloses that the peaks at 7.9, 10.3, 13.4, 15.1, 15.5, 17, 20.9 and 21.7 are major characteristic peaks for Crystalline Form-C Hemihydrate of Upadacitinib. Crystalline Form-D Anhydrous of Upadacitinib disclosed in US 9951080 is characterized by X-ray diffraction pattern (PXRD) comprising the peaks at 4.0, 8.0, 9.7, 14.2, 14.5, 19.0 and 20.3° 2θ. US ‘080 further discloses that the peaks at 4.0, 9.7, 14.2, 14.5, 19.0 and 20.3° 2θ. are major characteristic peaks for Crystalline Form-D anhydrous of Upadacitinib. US 20220002306 A1 discloses a Crystalline form CSI of Upadacitinib (acetic acid solvate). US 20210380596 A1 discloses a Crystalline Form-CSII of Upadacitinib (Anhydrate). EP 3891151 A1 discloses a Crystalline Phosphate salt of Upadacitinib. WO 2020115213 A1 discloses acetic acid solvate of Upadacitinib. CN 112110929 A1 discloses Crystalline Forms of CM-I and CM-II of Upadacitinib. CN 112409362 A1 discloses Crystalline Forms of Upadacitinib intermediate. US 20220041611 A1 discloses crystal form-A of the Di-p-toluoyl-L-tartrate of Upadacitinib, oxalate of Upadacitinib and PTSA salt of Upadacitinib. WO 2021/244323 A1 discloses Crystal form CSIV of Upadacitinib (Sebacic acid Co-crystal) and Crystal form CSV of Upadacitinib (Glutaric acid Co-crystal). US 20220204519 A discloses a Crystal form CSVI of Upadacitinib (Succinic acid Co-crystal) and Crystal form CSVII of Upadacitinib (Adipic acid Co-crystal). IN 202041025283 A discloses a crystalline Form-US of Upadacitinib and succinic acid (co-crystal). IN 202041052794 A discloses a Crystalline Form-UF of Upadacitinib and fumaric acid. The above prior art references disclose various polymorphic forms of Upadacitinib free base. None of the prior art discloses co-crystals of Upadacitinib and Diacetyl- D-tartaric acid (DATA). The inventors of the present invention have developed a novel co-crystal of Upadacitinib and Diacetyl-D-tartaric acid which is more stable and suitable for making formulation. SUMMARY OF THE INVENTION The present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ± 0.2° 2θ and further peaks at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ± 0.2° 2θ” and process for the preparation thereof. The present invention further provides Co-crystal of Upadacitinib and Diacetyl-D- tartaric acid (DATA) characterized in that its powder X-ray powder diffraction pattern is basically the same as that of FIG.1. The present invention also provides a process for preparing the compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), Formula-I
Figure imgf000007_0001
Diacetyl-D-tartaric acid (DATA) comprising the steps of: a) reacting compound of Formula-Va, Formula-Va
Figure imgf000007_0002
with compound of Formula-VI Formula-VI in presence of a base in a suitable solvent to produce compound of Formula- XIII. Formula-XIII
Figure imgf000008_0001
b) cyclizing the compound of Formula-XIII in-situ in presence of Trifluoroacetic anhydride (TFAA) in a suitable solvent to produce compound of Formula-XIV. Formula-XIV
Figure imgf000008_0002
c) deprotecting the compound of Formula-XIV in-situ in presence of an acid in a suitable solvent followed by treating with (+)-Di-p-toluoyl-D-tartaric Acid (DPTA) in an alcohol solvent to produce compound of Formula-XV. Formula-XV
Figure imgf000008_0003
d) reacting the compound of Formula-XV with 2,2,2-trifluoroethanamine or it’s salt in presence of Carbonyldiimidazole (CDI) and a base in a suitable solvent to produce compound of Formula-XVI. Formula-XVI
Figure imgf000009_0001
e) deprotecting the compound of Formula-XVI in presence of a base in a suitable solvent followed by treating with p-Toluenesulfonic acid to produce a compound of Formula-XVII. XVII
Figure imgf000009_0002
f) treating the compound of Formula-XVII with Diacetyl-D-Tartaric acid in a suitable solvent followed by adding anti-solvent and precipitation the compound of Formula-I. DESCRIPTION OF THE DRAWINGS: Figure 1: Illustrates the Single Crystal X-ray Diffraction (SCXRD) diagram of compound of Formula-I which is a co-crystal of Upadacitinib and Diacetyl-D- tartaric acid (DATA). Figure 2: Illustrates the PXRD diagram of compound of Formula-I which is a co- crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA). DETAILED DESCRIPTION OF THE INVENTION The present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1,7.4, 9.7, 10.6, 12.5, 14.3, 15.9, 16.5, 21.3 and 24.8° ± 0.2° 2θ” and process for the preparation thereof. The present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ± 0.2° 2θ and further the peaks at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ± 0.2° 2θ” and process for the preparation thereof. The present invention further provides a Co-crystal of Upadacitinib and Diacetyl- D-tartaric acid characterized in that its X-ray powder diffraction pattern is basically the same as that of FIG.1. In another embodiment, the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD), wherein the peak at 7.9 and 10.3 are absent in the PXRD of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid in the present invention. In another embodiment, the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD), wherein the peak at 4.0 is absent in the PXRD of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid in the present invention. The present invention further provides Co-crystal comprises Upadacitinib and Diacetyl-D-tartaric acid within the same crystalline phase in a molar ratio of 1: 0.5. Single Crystal X-ray Diffraction (SCXRD) for Upadacitinib and Diacetyl-D- tartaric acid (1:0.5) co-crystal: SCXRD measurements of the Upadacitinib and Diacetyl-D-tartaric acid crystallized in the monoclinic Crystal system with the C2 Space group and consists of four Upadacitinib molecules with two molecules of Diacetyl-D-tartaric acid (DATA) co-former (1:0.5) in the asymmetric unit as shown below as Figure-1.
Figure imgf000011_0001
Fig-1: Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of arbitrary radii. Hydrogen bonds are shown by dashed lines. Table 1. Crystal data and structure refinement for Upadacitinib diacetyl-D-tartaric acid co-crystal. Identification code Upadacitinib diacetyl-D-
Figure imgf000011_0002
crystal Empirical formula 2(C17H19F3N6O), C8H10O8 Formula weight 994.92 Temperature 294(2) K Wavelength 0.71073 A Crystal system Monoclinic Space group C2 Unit cell dimensions a = 25.1095(5) Ao α= 90°. b = 23.3596(5) Ao β= 108.9710(8)°. c = 20.3721(4) Ao γ = 90°. Volume 11300.2(4) A3 Z 8 Density (calculated) 1.170 Mg/m3 Absorption coefficient 0.098 mm-1 F(000) 4144 Crystal size 0.220 x 0.180 x 0.090 mm3 θ range for data collection 1.057 to 25.000° Index ranges -29<=h<=29, -27<=k<=27, -24<=1<=24 Reflections collected 105460 Independent reflections 19888 [R(int) = 0.0774] Completeness to θ = 25.000° 100.0% Absorption correction Semi-empirical from equivalents Max. and min. transmission 0.7461 and 0.6055 Refinement method Full-matrix least-squares on F2 Data / restraints / parameters 19888 / 159 / 1270 Goodness-of-fit on F2 1.076 Final R indices [I>26(I)] R1 = 0.1041, wR2 = 0.2558 R indices (all data) R1 = 0.1533, wR2 = 03091 Absolute structure parameter 0.3(3) Extinction coefficient 0.0046(6) Largest diff. peak and hole 0.726 and -0.902 e. Ao -3 Measurement Bruker D8 QUEST PHOTON-III Detector Software Used SHELXTL-PLUS Refinement: The X-ray data for Upadacitinib diacetyl-D-tartaric acid was collected at a room temperature on a Bruker D8 QUEST instrument with an IµS Mo microsource (λ=0.7107) and a PHOTON-III detector. The raw data frames were reduced and corrected for absorption effects using Bruker Apex 3 software suite programs. The structure was solved using the intrinsic phasing method and was further refined with the SHELXL program and expanded using Fourier techniques. Anisotropic displacement parameters were included for all non-hydrogen atoms. All N, O, and C bounded H atoms were positioned geometrically and treated as riding on their parent C atoms. The solvent molecules were not identified in different Fourier maps; hence, the squeeze command was applied to remove the solvent contribution to crystal structure. The absolute configuration has been assigned by reference to an unchanged chiral in the synthetic procedure. The hydrogen-bonding interactions in the crystal structure of Upadacitinib diacetyl-D-tartaric acid are shown below in Table-2. Table-3: Hydrogen bonds for Upadacitinib diacetyl-D-tartaric acid co-crystal [Ao and °].
Figure imgf000013_0001
Figure imgf000013_0002
In another embodiment of the present invention, the co-crystal may be present in crystalline form or amorphous form. More preferably, the co-crystal may be present in crystalline form. The present invention also provides a process for preparing the compound of Formula-I of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), comprising the steps of: a) reacting compound of Formula-Va, with compound of Formula-VI in presence of a base in a suitable solvent to produce compound of Formula- XIII. b) cyclizing the compound of Formula-XIII in-situ in presence of Trifluoroacetic anhydride (TFAA) in a suitable solvent to produce compound of Formula-XIV. c) deprotecting the compound of Formula-XIV in-situ in presence of an acid in a suitable solvent followed by treating with (+)-Di-p-toluoyl-D-tartaric Acid (DPTA) in an alcohol solvent to produce compound of Formula-XV. d) reacting the compound of Formula-XV with 2,2,2-trifluoroethanamine or its salt in presence of Carbonyldiimidazole (CDI) and a base in a suitable solvent to produce compound of Formula-XVI. e) deprotecting the compound of Formula-XVI in presence of a base in a suitable solvent followed by treating with p-Toluenesulfonic acid acid to produce compound of Formula-XVII. f) treating the compound of Formula-XVII with Diacetyl-D-Tartaric acid in a suitable solvent followed by adding anti-solvent to produce compound of Formula-I. The base used in Step-a) is an organic or inorganic base. The organic base is selected from N,N-diisopropylamine, N,N-diisopropylethylamine triethylamine, N,N- dimethylamine, trimethylamine, pyridine; the inorganic base is selected from sodium hydride, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate, or mixture thereof. preferably sodium hydride. The solvent used in step a) is an organic solvent, for example an aprotic polar solvent comprises N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixture thereof preferably dimethylformamide; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. The reaction may be performed from -60°C to 60° C for 30 min to 48 hours and then compound of Formula-XIII can be obtained by a usual procedure. The obtained compound-XIII can be used in the next reaction directly without isolation. The solvent used in step b) is an organic solvent, for example an aprotic polar solvent. Appropriate aprotic polar solvents can comprise N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixtures thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. preferably Acetonitrile. The reaction may be performed from 30°C to 90° C for 30 min to 48hours and then compound of Formula-XIV can be obtained by a usual procedure. The obtained compound-XIVcan be used in the next reaction directly without isolation. The acid used in step c) can be an inorganic acid comprising HCl, HBr in water or in organic solvents Methanol, Isopropyl alcohol acetic acid preferably HBr in acetic acid. The solvent used in step c) is an organic solvent, for example an aprotic polar solvent comprises N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixture thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, 2-Ethoxyethyl acetate or mixture thereof organic acid comprises Formic acid, Acetic acid Propionic acid or mixture thereof preferably Acetic acid The organic acid used in step c) is selected from tartaric acid, Dibenzoyl-D-tartaric acid, Di-p-toluoyl-D-tartaric acid, Diacetyl-D-tartaric acid or mixture thereof preferably Di-p-toluoyl-D-tartaric acid The reaction may be performed from 0°C to 60° C for 30 min to 48 hours and then compound of Formula-XV can be obtained by a usual procedure. The base used in step d) is selected from triethylamine, N,N-diisopropylamine, N,N- diisopropylethylamine, N,N-dimethylamine, trimethylamine, pyridine or mixture thereof. The solvent used in step d) is an organic solvent, for example an aprotic polar solvent comprises dichloromethane, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, or mixture thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert- butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. The reaction may be performed from 0°C to 60° C for 30 min to 48hours and then compound of Formula-XVI can be obtained by a usual procedure. The obtained compound-XVI can be used in the next reaction directly without isolation. The base used in step e) is selected from sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate, or mixture thereof. The suitable solvent used in step e) is selected from tetrahydrofuran, dichloromethane, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, water or mixture thereof preferably tetrahydrofuran; The reaction may be performed from 0°C to 60° C for 30 min to 48 hours and then compound of Formula-XVII can be obtained by a usual procedure. The suitable solvent used in step f) is an organic solvent, for example an alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ester comprises ethyl acetate, methyl acetate, n-butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. The anti-solvent used in step f) is selected from ethyl acetate, methyl acetate, n- butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. Preferably n-butyl acetate. The reaction may be performed from 0°C to 60° C for 30 min to 48hours and then compound of Formula-I of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA). Advantages of present invention: 1. The above reaction scheme is straightforward; minimizes the unit operation, and isolates the intermediate as filterable solid. 2. Controlling of racemization and achieving required chemical and chiral purity. 3. Prepared stable co-crystal with Diacetyl-D-Tartaric acid (DATA). The following examples are provided to illustrate the invention and are merely for illustrative purpose only and should not be construed to limit the scope of the invention. EXAMPLES: EXAMPLE-1: PREPARATION OF (3R,4S)-3-[2-[[(1,1-DIMETHYLETHOXY) CARBONYL][5-[(4-METHYLPHENYL)SULFONYL]-5H-PYRROLO[2,3-b] PYRA-ZIN-2-YL]AMINO]ACETYL]-4-ETHYL-1-PYRROLIDINE CARBOXYLICACID PHENYL METHYL ESTER OF FORMULA-XIII. DMF (1.0 L) was charged and cooled to 0-5°C in a round bottom flask and added sodium hydride (26.1 g, 1.1 m.eq). Compound of Formula-VI (250.0 g, 1.0 m.eq) was added to the above NaH/DMF (1.0 L) mixture over 30-60 mins and stirred for 30 mins. at 0-5°C. The resultant mixture was cooled to -20 to -30°C and added a solution of compound of Formula-Va (250.7 g, 1.1 m.eq in DMF (0.5 L)) over 30-60 mins. The mixture was then agitated for two hrs at -20 to -30°C. The reaction mixture was quenched with a mixture of acetic acid (38.6 g, 1.0 m.eq) and DMF (40 mL) mixture after the reaction was completed by HPLC. The product was extracted with toluene twice (2.5 L, 1.25 L) and the combined organic layers were washed with sodium chloride (1.25 L). The organic layer is concentrated and co-distilled with acetonitrile to get Compound of Formula-XIII as a syrupy mass. The resulted syrupy mass dissolved in acetonitrile (2.5 L) and used for next step. EXAMPLE-2: PREPARATION OF (3S,4R)-3-ETHYL-4-[3-[(4-METHYL PHENYL)SULFONYL]-3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]PYRAZIN-8-YL]-1- PYRROLIDINE CARBOXYLIC ACID PHENYLMETHYL ESTER OF FORMULA-XIV. To a solution of Compound of Formula-XIII in acetonitrile, trifluoroacetic anhydride (270.3 g, 1.28 moles) was added the mixture was warmed to 70-75°C and stirred for 4 hours. After completing the reaction on seen by HPLC, the mixture was cooled to 65- 70°C and concentrated, yielding a syrupy mass of Compound of Formula-XIV (500ml), which was used for next step without further isolation. EXAMPLE-3: PREPARATION OF 8-[(3R,4S)-4-ETHYL-3-PYRROLIDINYL]-3- [(4-METHYLPHENYL)SULFONYL]-3H-IMIDAZO[1,2-a]PYRROLO[2,3-e] PYRAZINE, (2S,3S)-2,3-BIS[(4-METHYLBENZOYL)OXY]-BUTANEDIOIC ACID (1:0.5) OF FORMULA-XV A solution of Compound of Formula-XIV in acetic acid (832 g, 3.21 moles) was added to HBr in acetic acid (832 g, 3.21 moles) maintain temperature of 0-10°C. The reaction mixture was agitated at 25-30°C for 2 hours, after which the mass was diluted with DM water and washed three times with MTBE (5000 mL). Then the aqueous layer is back- extracted with dichloromethane (2*1250 mL) after pH adjustment by using aqueous ammonia (500 mL) at 0-10°C. The combined organic layers were washed with DM water (1250 mL) and the organic layers were concentrated under reduced pressure. The resulting crude compound was dissolved in methanol (2125 mL), added the Di-p- toluoyl-D-Tartaric acid (136.7g, 0.35 moles) in methanol (2125 mL), and maintained for 30 minutes at 25-30°C followed by 2 hours at 50-55°C. The salt was agitated at 20- 30°C, then 0-5°C and the solid was filtered to yield pure Compound of Formula-XV (198.2g). Yield 51%; HPLC purity is 99.33%, and Chiral HPLC purity is 99.87%. EXAMPLE-04: PREPARATION OF (3S,4R)-3-ETHYL-4-[5-(P-TOLYL SULFONYL)-1,5,7,10-TETRAZATRICYCLO[7.3.0.02,6]DODECA-2(6),3,7,9, 11-PENTAE-N-12-YL]-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1- CARBOXAMIDE OF FORMULA-XVI. To a cooled 0-5°C suspension of 2,2,2-Trifluoroethylamine hydrochloride (75.73g, 1.5 m.eq) dichloromethane (900 mL), added the CDI (90.8g 1.5 m.eq) followed by triethylamine (56.6 g, 1.5 m.eq). The reaction was maintained at 0-5°C for 2-2.5 hrs, and then added a solution of Formula-XV. After completing the reaction on seen by HPLC, added the pre-cooled DM water (1125 mL, 10°C), mix for 30 minutes, and separate the organic layer with aqueous hydrochloric acid and sodium bicarbonate. Separated the organic layer, concentrated under reduced pressure resulting compound of Formula-XVI as a syrup, and dissolved in THF (2250 ml). Note: Compound of formula-XV free base solution was (225g 1.0 m.eq) was prepared by liberating salt with sodium hydroxide solution (112 mL. 1.5 m.eq) and extracting with Dichloromethane (2250 mL) and used for next step without further isolation. EXAMPLE-05: PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a] PYRROLO[2,3-e]PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROMETHYL)- PYRROLIDINE-1-CARBOXAMIDE, SODIUM P-TOLUENESULFONATE OF FORMULA-XVII. To a solution of compound Formula-XVI in THF (2250 mL) added 50% sodium hydroxide solution (104.52g, 3.5 m.eq) at 25-30°C, maintained the reaction mixture at 50-55°C for 60-75 min, upon completion of the reaction by HPLC, cooled the reaction mixture to 25-30°C and maintained for 3-3.5h at 25-30°C. The precipitated solid was filtered and washed with THF (450 mL), dried under suction to yield compound of Formula-XVII (290g), which was used for next step without any further isolation or purification. EXAMPLE-06: PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2- a]PYRROLO[2,3-e]PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROMETHYL)- PYRROLIDINE-1-CARBOXAMIDE,(+)DIACETYL-D-TARTARICACID (1:0.5) OF FORMULA-I. Compound of Formula-XVII (290g) was added to ethyl acetate (2250 mL) and agitated for 10 minutes before adding DM water (1125 mL) and stirring for another 30 mins. The organic layer was separated, the aqueous layer was successively extracted with Ethyl acetate (1125 mL), and the combined organic layer was washed with sodium bicarbonate solution and DM water (1125 mL). After charcoal treatments concentrated under reduced pressure. Co-distilled twice with Isopropyl alcohol. Thereafter added isopropyl alcohol (337.5 mL), stirred for 15 minutes, then added (+)-Diacetyl-D- tartaric acid (48 g) in n-Butyl acetate (450 mL) solution, stirred for 90 minutes. Thereafter added n-Butyl acetate (10800 mL) agitated for 20-21h, resulting solid was filtered, washed with n-Butyl acetate (450 mL), suction dried under vacuum for 30 min and dried under vacuum to obtain Compound of Formula-I of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid of Formula-I. Yield: 75%. HPLC purity: 99.97%.

Claims

We Claim: 1. A Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA). 2. A Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by a PXRD pattern comprising the peaks at about 5.3, 6.1, 7.4 and 16.5°± 0.
2° 2θ. 3. The co-crystal as claimed in claim 2, further characterized by one or more additional peaks at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.
3 and 24.8° ± 0.2° 2θ.
4. A process for preparing a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, Formula-I
Figure imgf000021_0001
Diacetyl-D-tartaric acid comprising the steps of: a) reacting compound of Formula-Va, Formula-Va
Figure imgf000021_0002
with compound of Formula-VI, Formula-VI
Figure imgf000021_0003
in presence of a base in a suitable solvent to produce compound of Formula- XIII. 1 Formula-XIII b) cyclizing the compound of Formula-XIII in-situ in presence of Trifluoroacetic anhydride (TFAA) in a suitable solvent to produce compound of Formula-XIV. Formula-XIV
Figure imgf000022_0001
c) deprotecting the compound of Formula-XIV in-situ in presence of an acid in a suitable solvent followed by treating with (+)-Di-p-toluoyl-D-tartaric Acid (DPTA) in an alcohol solvent to produce compound of Formula-XV. Formula-XV
Figure imgf000022_0002
d) reacting the compound of Formula-XV with 2,2,2-trifluoroethanamine or it’s salt in presence of Carbonyldiimidazole (CDI) and a base in a suitable solvent to produce compound of Formula-XVI. 2 Formula-XVI e) deprotecting the compound of Formula-XVI in presence of a base in a suitable solvent followed by treating with p-Toluenesulfonic acid to produce compound of Formula-XVII. f) treating the compound of Formula-XVII with Diacetyl-D-Tartaric acid (DATA) in a suitable solvent followed by adding anti-solvent and precipitation the compound of Formula-I.
5. The process as claimed in claim 4, wherein, In step-a) the base used is selected from the group consisting of diisopropylamine, diisopropylethylamine triethylamine, N,N-dimethylamine, trimethyl amine, pyridine, sodium hydride, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate and mixtures thereof; In step a) the suitable solvent used is selected from the group consisting of dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert- butylalcohol, isoamylalcohol, 2-methoxyethanol, acetone, methylisobutylketone, 2-pentanone, ethyl methyl ketone, diethyl ketone, ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate and 2-methoxyethyl acetate, and mixtures thereof.
6. The process as claimed in claim 4, wherein, In step-b) the suitable solvent used is selected from the group consisting of N,N- dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert- butyl alcohol, isoamylalcohol, 2-methoxyethanol, acetone, methyl isobutyl 3 ketone, 2-pentanone, ethyl methyl ketone, diethyl ketone, ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate, and mixtures thereof.
7. The process as claimed in claim 4, wherein, In step c) the acid used is selected from HCl or HBr in an aqueous or in an organic solvent selected from the group consisting of methanol, isopropyl alcohol and acetic acid and mixtures thereof; In step c) the suitable solvent used is selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert- butylalcohol, isoamylalcohol and 2-methoxyethanol and mixtures thereof.
8. The process as claimed in claim 4, wherein, In step d) the base used is selected from the group consisting of triethylamine, diisopropylamine, diisopropylethylamine, dimethylamine, trimethyl amine, and pyridine; In step d) the suitable solvent used is selected from the group consisting of dichloromethane, dimethylformamide, dimethylsulfoxide, acetonitrile, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert- butylalcohol, isoamylalcohol, 2-methoxyethanol, acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone, ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, 2-methoxyethyl acetate, and mixtures thereof.
9. The process as claimed in claim 4, wherein, In step e) the base used is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate and mixtures thereof; In step e) the suitable solvent used is selected from the group consisting of tetrahydrofuran, dichloromethane, N,N-dimethylformamide, dimethylsulfoxide and acetonitrile and mixtures thereof. 4
10. The process as claimed in claim 4, wherein, In step f) the suitable solvent used is selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol, ethyl acetate, methyl acetate, n-butyl acetate, isopropyl acetate, and methoxy ethyl acetate; In step f) the anti-solvent used is selected from the group consisting of ethyl acetate, methyl acetate, n-butyl acetate, isopropyl acetate and 2-methoxyethyl acetate and mixtures thereof. 5
PCT/IN2022/051056 2022-10-03 2022-12-06 Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof WO2024075131A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202241056709 2022-10-03
IN202241056709 2022-10-03

Publications (1)

Publication Number Publication Date
WO2024075131A1 true WO2024075131A1 (en) 2024-04-11

Family

ID=90607795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2022/051056 WO2024075131A1 (en) 2022-10-03 2022-12-06 Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof

Country Status (1)

Country Link
WO (1) WO2024075131A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066775A1 (en) * 2015-10-16 2017-04-20 Abbvie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
WO2020224633A1 (en) * 2019-05-09 2020-11-12 苏州鹏旭医药科技有限公司 Upadacitinib salt compound and preparation method therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066775A1 (en) * 2015-10-16 2017-04-20 Abbvie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
WO2020224633A1 (en) * 2019-05-09 2020-11-12 苏州鹏旭医药科技有限公司 Upadacitinib salt compound and preparation method therefor

Similar Documents

Publication Publication Date Title
US8969558B2 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
US8329696B2 (en) Solid state forms of sitagliptin salts
US20090221595A1 (en) Crystalline form of sitagliptin
US20100041885A1 (en) Crystalline forms of sitagliptin phosphate
JP5735659B2 (en) Method for producing sitagliptin intermediate
KR20050030961A (en) Modified pictet-spengler reaction and products prepared therefrom
TWI771342B (en) Preparation method for pyrrole six-membered heteroaryl ring derivative and intermediate thereof
US8183373B2 (en) Solid state forms of sitagliptin salts
TW201718516A (en) Crystalline forms of a histone deacetylase inhibitor
WO2019167085A1 (en) Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
JP2020534331A5 (en)
TW202210461A (en) Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
WO2024075131A1 (en) Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof
WO2020053795A2 (en) Process for the preparation of acalabrutinib and its intermediates
EP2220082B1 (en) Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
WO2023001299A1 (en) Crystal form of compound represented by formula i, and preparation therefor and application thereof
TWI842342B (en) A preparation method of a DPP-IV inhibitor and its key intermediate
WO2024092892A1 (en) Edoxaban intermediate and preparation method therefor
US11858901B2 (en) 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix
WO2008004416A1 (en) Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound
CN117843643A (en) Preparation method of sitagliptin phosphate
TW202330535A (en) Preparation method of DPP-IV inhibitor and key intermediate thereof
AU2015376077A1 (en) Novel process for the preparation of dipeptidyl peptidase-4 (DDP-4) enzyme inhibitor
JP2006512322A (en) A novel process for the preparation of imidazolyl compounds
JPH1180132A (en) Production of 2-piperazinecarboxylic acid salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22961335

Country of ref document: EP

Kind code of ref document: A1